BIGBEAR
PHARMACEUTICAL
Pralsetinib inhibits the abnormal activation of RET protein and blocks downstream signaling pathways.
AuthenticGuaranteeFast DeliveryPrivacy CStone Pharmaceuticals partner Blueprint Medicines recently announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Admin···【More】
Update: 23 Mar,2026Source: BigbearViews: 83
Blueprint Medicines recently announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib), a precision oncology drug,···【More】
Update: 23 Mar,2026Source: BigbearViews: 86
Recently, the U.S. Food and Drug Administration (FDA) approved Gavreto (pralsetinib) capsules, a precision oncology drug and RET kinase inhibitor, for···【More】
Update: 23 Mar,2026Source: BigbearViews: 83
China's National Medical Products Administration (NMPA) recently approved Prugihua® (pralsetinib capsules) as a Class 1 New Drug Application for t···【More】
Update: 23 Mar,2026Source: BigbearViews: 104
The U.S. Food and Drug Administration (FDA) announced on August 9 that it has fully approved Gavreto (pralsetinib) for the treatment of adult patients···【More】
Update: 23 Mar,2026Source: BigbearViews: 97
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
